title: Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
abstract: OBJECTIVE
  To compare exenatide and sitagliptin glucose and glucoregulatory measures in subjects with type 2 diabetes.
  
  
  METHODS
  An 8-week, double-blind, randomized, crossover, single-centre study. Eighty-six subjects (58% female, body mass index 35 ± 5 kg/m², haemoglobin A1c 8.3 ± 1.0%) received either exenatide 10 µg (subcutaneous) twice daily or sitagliptin 100 mg (oral) daily for 4 weeks and crossed to the other therapy for an additional 4 weeks. Main outcome was time-averaged glucose during the 24-h inpatient visits.
  
  
  RESULTS
  Both treatments decreased average 24-h glucose, but exenatide had a greater effect [between-group difference: -0.67 mmol/l, 95% confidence interval (CI): -0.9 to -0.4 mmol/l]. Both treatments decreased 2-h postprandial glucose (PPG), area under the curve of glucose above 7.8 mmol/l (140 mg/dl) and 11 mmol/l (200 mg/dl) and increased the time spent with glucose between 3.9 and 7.8 mmol/l (70 and 140 mg/dl) during 24 h, but exenatide had a significantly greater effect (p < 0.05). Both treatments decreased postprandial serum glucagon, with exenatide having a greater effect (p < 0.005). Both treatments decreased fasting blood glucose to a similar degree (p = 0.766). Sitagliptin increased, while exenatide decreased, postprandial intact glucagon-like peptide-1. Both drugs improved homeostasis model assessment of β-cell function (HOMA-B), with exenatide having a significantly greater effect (p = 0.005). Both exenatide and sitagliptin decreased 24-h caloric intake, with exenatide having a greater effect (p < 0.001). There was no episode of major hypoglycaemia. Adverse events were mild to moderate and mostly gastrointestinal in nature with exenatide. No study withdrawals were due to an adverse event.
  
  
  CONCLUSIONS
  Compared to sitagliptin, exenatide showed significantly lower average 24-h glucose, 2-h PPG, glucagon, caloric intake and improved HOMA-B.
authors: Cetero Research, San Antonio, TX, USA. jolene.berg@cetero.com
authors: J K
authors: JK
authors: Berg
authors: S K
authors: SK
authors: Shenouda
authors: C R
authors: CR
authors: Heilmann
authors: A L
authors: AL
authors: Gray
authors: J H
authors: JH
authors: Holcombe
references: Metabolism. 2001 May;50(5):583-9
references: 11319721
references: Diabetes Care. 2010 Jul;33(7):1509-15
references: 20357372
references: Curr Med Res Opin. 2008 Oct;24(10):2943-52
references: 18786299
references: Diabetes Care. 2005 Jun;28(6):1282-8
references: 15920040
references: Diabetes Care. 2003 Nov;26(11):3080-6
references: 14578243
references: JAMA. 1997 Mar 19;277(11):925-6
references: 9062334
references: Diabetes Care. 2004 Jun;27(6):1487-95
references: 15161807
references: Am J Health Syst Pharm. 2005 Jan 15;62(2):173-81
references: 15700891
references: Diabetes Care. 2010 May;33(5):951-7
references: 20107105
references: Biometrics. 1965 Jun;21:467-80
references: 14338679
references: Diabetes Care. 2006 Dec;29(12):2638-43
references: 17130197
references: Am J Physiol Endocrinol Metab. 2008 May;294(5):E846-52
references: 18334612
references: J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9
references: 16912128
references: Clin Ther. 2008 May;30(5):858-67
references: 18555933
references: Cell Metab. 2006 Mar;3(3):153-65
references: 16517403
references: Clin Pharmacol Ther. 2005 Dec;78(6):675-88
references: 16338283
references: Am J Physiol. 1999 Aug;277(2):E283-90
references: 10444424
references: J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9
references: 12843147
references: Diabetes Care. 2009 May;32(5):762-8
references: 19196887
references: Am J Physiol Endocrinol Metab. 2001 Jul;281(1):E155-61
references: 11404233
references: Diabetes Care. 2006 Dec;29(12):2632-7
references: 17130196
references: Diabetes. 2004 Sep;53(9):2397-403
references: 15331551
references: Int J Obes Relat Metab Disord. 2001 Jun;25(6):781-92
references: 11439290
references: Diabetes Care. 2005 Feb;28(2):260-5
references: 15677776